Literature DB >> 1860736

A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA).

H Kaufman1, J Schlom, J Kantor.   

Abstract

Carcinoembryonic antigen (CEA) is a 180-kDa glycoprotein expressed on most gastrointestinal carcinomas. A 2.4-kb cDNA clone, containing the complete coding sequence, was isolated from a human colon tumor cell library and inserted into a vaccinia virus genome. This newly developed construct was characterized by Southern blotting, DNA hybridization studies, and polymerase chain reaction analysis. The CEA gene was stably integrated into the vaccinia virus thymidine kinase gene. The recombinant was efficiently replicated upon serial passages in cell cultures and in animals. The recombinant virus expresses on the surface of infected cells a protein product recognized by a monoclonal antibody (COL-I) directed against CEA. Immunization of mice with the vaccinia construct elicited a humoral immune response against CEA. Pilot studies also showed that administration of the recombinant CEA vaccinia construct was able to greatly reduce the growth in mice of a syngeneic murine colon adenocarcinoma which had been transduced with the human CEA gene. The use of this new recombinant CEA vaccinia construct may thus provide an approach in the specific active immunotherapy of human GI cancer and other CEA expressing carcinoma types.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1860736     DOI: 10.1002/ijc.2910480618

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

Review 1.  The next wave of recombinant and synthetic anticancer vaccines.

Authors:  K R Irvine; N P Restifo
Journal:  Semin Cancer Biol       Date:  1995-12       Impact factor: 15.707

2.  Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer.

Authors:  D McAneny; C A Ryan; R M Beazley; H L Kaufman
Journal:  Ann Surg Oncol       Date:  1996-09       Impact factor: 5.344

3.  Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model.

Authors:  H L Kaufman; J B Rao; K R Irvine; V Bronte; S A Rosenberg; N P Restifo; K R Irivine
Journal:  J Immunother       Date:  1999-11       Impact factor: 4.456

4.  Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.

Authors:  Jeffrey Schlom; Sofia R Gameiro; Kristin C Hicks; Karin M Knudson; Karin L Lee; Duane H Hamilton; James W Hodge; William D Figg; Peter Ordentlich; Frank R Jones; Shahrooz Rabizadeh; Patrick Soon-Shiong
Journal:  Clin Cancer Res       Date:  2019-10-23       Impact factor: 12.531

5.  Viral vectors for vaccine applications.

Authors:  Youngjoo Choi; Jun Chang
Journal:  Clin Exp Vaccine Res       Date:  2013-07-03

Review 6.  Poxviral vectors for cancer immunotherapy.

Authors:  Joseph W Kim; James L Gulley
Journal:  Expert Opin Biol Ther       Date:  2012-04       Impact factor: 4.388

Review 7.  Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer.

Authors:  J Schlom; J Kantor; S Abrams; K Y Tsang; D Panicali; J M Hamilton
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

8.  Evaluation of human carcinoembryonic-antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapies.

Authors:  P H Hand; P F Robbins; M L Salgaller; D J Poole; J Schlom
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

Review 9.  Animal models of human-derived cancer vaccines.

Authors:  D Herlyn; R Somasundaram; W Li; L Jacob
Journal:  Cell Biophys       Date:  1995-08

Review 10.  Immunotherapy for colorectal cancer.

Authors:  K A Foon
Journal:  Curr Oncol Rep       Date:  2001-03       Impact factor: 5.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.